{"id":"ri-002","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":{"chemblId":"CHEMBL4303334","moleculeType":"Small molecule","molecularWeight":"612.64"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"RI-002 is derived from human plasma and contains a broad spectrum of immunoglobulins (primarily IgG) collected from multiple donors. It is administered intravenously to provide immediate passive immune protection and modulate immune responses in patients with immunodeficiency or certain autoimmune conditions. The polyclonal antibody preparation helps restore or enhance the patient's ability to fight infections and regulate inflammatory responses.","oneSentence":"RI-002 is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering polyclonal human antibodies to boost immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:23.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency in hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT01814800","phase":"PHASE3","title":"Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"COMPLETED","sponsor":"ADMA Biologics, Inc.","startDate":"2014-02","conditions":"Primary Immune Deficiency Disorder","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune Globulin (Human)"],"phase":"phase_3","status":"active","brandName":"RI-002","genericName":"RI-002","companyName":"ADMA Biologics, Inc.","companyId":"adma-biologics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"RI-002 is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering polyclonal human antibodies to boost immune function. Used for Primary immunodeficiency disorders, Secondary immunodeficiency in hematologic malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}